Sep 2026· Precision Medical Sciences· 0 citations· 101 references
TL;DR
This review comprehensively synthesizes the evolutionary trajectory of genomic, transcriptomic, epigenetic, and spatial multi‐omic diagnostic pipelines and provides a unified, cross‐disciplinary blueprint to accelerate the transition of precision oncology from data‐rich analytical exploration to definitive clinical execution.
Abstract
Precision oncology has initiated a profound paradigm shift in clinical cancer care, replacing historical, empirical treatment models with highly individualized, multi‐omics‐driven therapeutic strategies. However, translating high‐throughput analytical insights into universal bedside execution remains a formidable challenge due to technological fragmentation and systemic bottlenecks. This review comprehensively synthesizes the evolutionary trajectory of genomic, transcriptomic, epigenetic, and spatial multi‐omic diagnostic pipelines. We dissect how the clinical integration of next‐generation sequencing, single‐cell diagnostics, and high‐resolution spatial mapping has refined patient stratification and enabled the deployment of next‐generation modalities, including tumor‐agnostic therapies, antibody‐drug conjugates, and individualized neoantigen mRNA vaccines. Furthermore, we critically evaluate the emergence of functional precision medicine platforms, specifically patient‐derived tumor organoids, for in vitro drug screening alongside real‐time, longitudinal monitoring via liquid biopsies and minimal residual disease tracking. Finally, we examine the pivotal role of artificial intelligence in translating big data into actionable clinical workflows while addressing the regulatory, economic, and accessibility barriers impeding equitable global deployment. Ultimately, this work provides a unified, cross‐disciplinary blueprint to accelerate the transition of precision oncology from data‐rich analytical exploration to definitive clinical execution.
The role of single‐cell and spatial multi‐omics in decoding the tumour immune microenvironment and uncovering rare, aggressive cellular subpopulations responsible for therapeutic resistance is emphasised and metabolomics—particularly lipid metabolic reprogramming—in understanding adaptive resistance to tyrosine kinase...
Yuang Gao, Li-Yan Lin, Hong-Rui Zhou et al.· Clinical and Translational D...· 0 citations
The biological rationale rooted in the genomic basis of cancer and the concept of oncogene addiction is outlined, and the enabling technologies - next-generation sequencing, comprehensive genomic profiling, large reference atlases, and liquid biopsy - are described that have made molecular characterization feasible in...
Mohd Faizan Siddiqui· International Research Journ...· 0 citations
To improve reproducibility and worldwide applicability, future work will focus on standardizing biomarker validation, employing adaptive clinical trial designs, and integrating multi-omic data.
Keshava Kyatanahalli Shekharappa, Mohammad Ali· Current Chemical Biology· 0 citations
This conceptual workflow provides a stepwise translational roadmap from multi-omics discovery to clinical implementation, and is important to note that many of these applications remain at an early stage, with most evidence derived from small cohorts, preclinical models, or retrospective analyses, and prospective clini...
Sowhanur Rahman Nirob, Priyanshu Das, Md. Owafeeuzzaman Patwary et al.· Frontiers in Oncology· 0 citations
Quantitative co-clinical imaging provides a powerful framework to link genotype with function by confirming drug delivery, target engagement, pharmacodynamic effects, tumor function and heterogeneity across animal models and patients to advance functional precision medicine (FPM).
K. Shoghi, C. Badea, Donna M. Peehl et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.